Oak Ridge, TN, July 27, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated...
CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to...
Scientific Advisory Board Adds Multi-disciplinary Clinical and Scientific Expertise to Support Acceleration of the Company’s mdHACM Placental Biologics Pipeline MARIETTA,...
Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 PeopleTHE WOODLANDS, Texas, July 27,...
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:...
BANNOCKBURN, Ill., July 27, 2022 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH),...
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
World-class facility supports the company’s growth, and discovery and development of gene therapies for inherited retinal diseases Atsena Therapeutics Ribbon-cutting...
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021U.S. End User Demand up 45% vs....
SOUTH ORANGE, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing filtration and pathogen...
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be...
Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the...
ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to...
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused...
SALT LAKE CITY, UT , July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --UTMD achieved second calendar quarter (2Q) and first...
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...